Diabetes News You Can Use

Obesity may be tied to NAFLD risk in pediatric T1D

Measures of nonalcoholic fatty liver disease risk were similar for children with obesity and type 1 diabetes or obesity alone, according to a small study in the Journal of Diabetes and its Complications. Larger studies with MRI and liver biopsy data are needed, the study team reported.

 Full Story: Healio (free registration)/Endocrine Today (11/29)  

Study supports self-monitoring for T2D patients not receiving insulin

A study in the Journal of General Internal Medicine found that diabetes patients who didn’t take insulin but self-monitored their blood glucose had better A1C control compared with those who didn’t self-monitor their blood glucose. The study, based on data from 22 studies encompassing 6,204 individuals, also found that A1C control was better among those who monitored 8-11 times weekly with lifestyle adjustments.

 Full Story: Medical Dialogues (11/29)  

Study evaluates racial disparities in CV risk factors

A study in Scientific Reports found Mexican American and non-Hispanic Black adults had greater prevalence of hypertension, obesity and diabetes compared with white and Asian adults. There also were disparities in cardiovascular and cardiometabolic risk factors. Diet metrics were among the lowest, prompting study author and registered dietitian Stephanie Lopez-Neyman to urge health care providers to consider working with a RD who can develop “culturally tailored nutrition handouts for a cardiovascular disease or cardiometabolic risk factor they want their patient to work on in conjunction with physical activity and the medication prescribed.”

 Full Story: Healio (free registration) (11/22)  

Study links maternal comorbidities to kidney risks in offspring

A study published in JAMA Network Open found that maternal comorbidities, including preeclampsia, diabetes, obesity and maternal hypertension, were associated with increased risks for poor kidney function in offspring, highlighting that maternal preeclampsia was associated with an increase of high creatinine and urea concentrations in newborns. Findings were based on umbilical cord blood samples and venous blood samples of 12,938 infants.

 Full Story: Contemporary Pediatrics (11/22)  

Study: Early A1C screening may help diagnose T2D faster

A study in Diabetologia found that nearly 1% of the 166,846 adults ages 40 to 70 in the UK Biobank had undiagnosed type 2 diabetes as indicated by a 6.5% or higher A1C, and 87% of them went on to actually be diagnosed with the disease after a median of 2.2 years of follow-up. The findings also revealed that men and adults with obesity who had undiagnosed diabetes had a shorter time to diagnosis, compared with women and adults with a body mass index of less than 30 kg/m2, respectively.

 Full Story: Healio (free registration)/Endocrine Today (11/23)  

FDA OKs drug to delay onset of T1D

Provention Bio’s monoclonal antibody drug teplizumab is the first treatment to receive FDA approval for delaying the onset of insulin-dependent type 1 diabetes. It is designed for use in patients aged 8 or older who have at least two disease autoantibodies and show abnormal blood sugar stability.

 Full Story: Reuters (11/17)  

Rapid C-peptide loss tied to worse A1C in youths with T1D

Youths who experienced a rapid decline in C-peptide during the first six years of their type 1 diabetes diagnosis also had a greater likelihood of having higher A1C and more episodes of severe hypoglycemia, compared with those who didn’t have a rapid decline in C-peptide. The findings in BMJ Open Diabetes Research & Care also showed that “multiple autoantibodies and low age at diagnosis predict a rapid decline in the beta-cell function,” the researchers said.

 Full Story: Medical Dialogues (11/20)  

FDA approves 2nd biosimilar insulin for Lantus

Eli Lilly and Co.’s Rezvoglar has gained the FDA’s approval as the second interchangeable biosimilar for Lantus, or insulin glargine, for improving glycemic control in children and adults with diabetes. The approval will allow Rezvoglar to be substituted for insulin glargine at pharmacies without prescriber intervention.

 Full Story: eMPR (11/17)  

Study shows CV benefits of sotagliflozin in T2D patients

Patients with type 2 diabetes who were treated with sotagliflozin had a lower risk for cardiovascular death and heart failure-related events within the first 30 and 90 days after being discharged from the hospital. The findings, presented at the American Heart Association Scientific Sessions showed that sotagliflozin treatment among this population was also linked lower all-cause mortality risk.

 Full Story: Healio (free registration)/Cardiology Today (11/15)  

Study links nighttime light pollution, diabetes risk

A large study published in the journal Diabetologia showed that people who live and sleep in areas with a high level of artificial nighttime light pollution may have a 28% higher chance of developing diabetes than those in areas with low light pollution. Chronic exposure to the light pollution elevated blood glucose levels and contributed to increased risk of insulin resistance.

 Full Story: CNN (11/14)